IE44458B1 - Compositions for treating hypercholesterolemia - Google Patents
Compositions for treating hypercholesterolemiaInfo
- Publication number
- IE44458B1 IE44458B1 IE213/77A IE21377A IE44458B1 IE 44458 B1 IE44458 B1 IE 44458B1 IE 213/77 A IE213/77 A IE 213/77A IE 21377 A IE21377 A IE 21377A IE 44458 B1 IE44458 B1 IE 44458B1
- Authority
- IE
- Ireland
- Prior art keywords
- vitamin
- composition according
- fatty acid
- polyester
- fat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 118
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims description 20
- 229920000728 polyester Polymers 0.000 claims description 128
- 239000000194 fatty acid Substances 0.000 claims description 84
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 81
- 229930195729 fatty acid Natural products 0.000 claims description 81
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 69
- 229940088594 vitamin Drugs 0.000 claims description 69
- 229930003231 vitamin Natural products 0.000 claims description 69
- 235000013343 vitamin Nutrition 0.000 claims description 69
- 239000011782 vitamin Substances 0.000 claims description 69
- 239000007788 liquid Substances 0.000 claims description 68
- 239000003795 chemical substances by application Substances 0.000 claims description 57
- 150000004665 fatty acids Chemical class 0.000 claims description 49
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 47
- 229930006000 Sucrose Natural products 0.000 claims description 47
- 239000005720 sucrose Substances 0.000 claims description 47
- 229920005862 polyol Polymers 0.000 claims description 42
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 38
- 235000019155 vitamin A Nutrition 0.000 claims description 36
- 239000011719 vitamin A Substances 0.000 claims description 36
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 35
- -1 polyol fatty acid Chemical class 0.000 claims description 33
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 32
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 31
- 229940045997 vitamin a Drugs 0.000 claims description 31
- 235000012000 cholesterol Nutrition 0.000 claims description 28
- 235000019197 fats Nutrition 0.000 claims description 27
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 25
- 150000003077 polyols Chemical class 0.000 claims description 24
- 239000004615 ingredient Substances 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 19
- 235000000346 sugar Nutrition 0.000 claims description 17
- 235000019166 vitamin D Nutrition 0.000 claims description 17
- 239000011710 vitamin D Substances 0.000 claims description 17
- 239000011709 vitamin E Substances 0.000 claims description 17
- 235000019165 vitamin E Nutrition 0.000 claims description 17
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- 239000011712 vitamin K Substances 0.000 claims description 15
- 235000019168 vitamin K Nutrition 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 150000003626 triacylglycerols Chemical class 0.000 claims description 14
- 229930003316 Vitamin D Natural products 0.000 claims description 13
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 13
- 229940046008 vitamin d Drugs 0.000 claims description 13
- 229930003427 Vitamin E Natural products 0.000 claims description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 12
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 12
- 229940046009 vitamin E Drugs 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 229930003448 Vitamin K Natural products 0.000 claims description 11
- 150000005846 sugar alcohols Chemical class 0.000 claims description 11
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 11
- 229940046010 vitamin k Drugs 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 235000010356 sorbitol Nutrition 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 150000008163 sugars Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 235000019482 Palm oil Nutrition 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 239000002540 palm oil Substances 0.000 claims description 7
- 210000005070 sphincter Anatomy 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 239000004386 Erythritol Substances 0.000 claims description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 6
- 235000019868 cocoa butter Nutrition 0.000 claims description 6
- 229940110456 cocoa butter Drugs 0.000 claims description 6
- 235000019414 erythritol Nutrition 0.000 claims description 6
- 229940009714 erythritol Drugs 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 5
- 125000005313 fatty acid group Chemical group 0.000 claims description 5
- 235000013861 fat-free Nutrition 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 25
- 239000003925 fat Substances 0.000 description 24
- 239000000463 material Substances 0.000 description 19
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 239000003778 fat substitute Substances 0.000 description 9
- 239000003549 soybean oil Substances 0.000 description 9
- 235000012424 soybean oil Nutrition 0.000 description 9
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 8
- 235000013341 fat substitute Nutrition 0.000 description 8
- 239000000344 soap Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 7
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000012343 cottonseed oil Nutrition 0.000 description 7
- 239000002385 cottonseed oil Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229930182830 galactose Natural products 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XPXWDKLKEOUSOD-UHRUCXANSA-N [(2S,4R)-2,3,4,5-tetrakis[[(Z)-octadec-9-enoyl]oxy]pentyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H](COC(=O)CCCCCCC\C=C/CCCCCCCC)OC(=O)CCCCCCC\C=C/CCCCCCCC XPXWDKLKEOUSOD-UHRUCXANSA-N 0.000 description 6
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Natural products O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 235000021313 oleic acid Nutrition 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 240000008415 Lactuca sativa Species 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 4
- JIZCYLOUIAIZHQ-UHFFFAOYSA-N ethyl docosenyl Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC JIZCYLOUIAIZHQ-UHFFFAOYSA-N 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 230000002475 laxative effect Effects 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- QSQLTHHMFHEFIY-UHFFFAOYSA-N methyl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC QSQLTHHMFHEFIY-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- 235000012045 salad Nutrition 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003760 tallow Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 4
- URSCRKIYUPROKB-PHHCKKAISA-N (Z)-octadec-9-enoic acid (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O URSCRKIYUPROKB-PHHCKKAISA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- GQPAMKBZEBGASK-LVVDDXEGSA-N [(2r,3s)-2,3,4-tris[[(z)-octadec-9-enoyl]oxy]butyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GQPAMKBZEBGASK-LVVDDXEGSA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 235000010389 delta-tocopherol Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000013367 dietary fats Nutrition 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000000260 hypercholesteremic effect Effects 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DLQDPUCZIABCES-VZBBZXSKSA-N CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)C=O Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)C=O DLQDPUCZIABCES-VZBBZXSKSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 2
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 206010056474 Erythrosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- MKXYXDWCASGLJG-NSLUQPGISA-N OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O MKXYXDWCASGLJG-NSLUQPGISA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- WJPZXFWMBSJTPE-PISRTDAGSA-N [(2r,3r,4s,5r,6r)-6-[(2s,3s,4r,5r)-3,4-di(hexadecanoyloxy)-2,5-bis(hexadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-tri(hexadecanoyloxy)oxan-2-yl]methyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H]1[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](COC(=O)CCCCCCCCCCCCCCC)O[C@@]1(COC(=O)CCCCCCCCCCCCCCC)O[C@@H]1[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](OC(=O)CCCCCCCCCCCCCCC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](COC(=O)CCCCCCCCCCCCCCC)O1 WJPZXFWMBSJTPE-PISRTDAGSA-N 0.000 description 2
- LYAKYODQZBHMCI-YSVXLPCPSA-N [(2r,3r,4s,5r,6r)-6-[(2s,3s,4r,5r)-3,4-di(octadecanoyloxy)-2,5-bis(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-tri(octadecanoyloxy)oxan-2-yl]methyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H]1[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O1 LYAKYODQZBHMCI-YSVXLPCPSA-N 0.000 description 2
- WKTGPVRCJVGUCH-MYELPBIZSA-N [(2r,3r,4s,5s)-5-[(2r,3r,4s,5r,6r)-6-(hydroxymethyl)-3,4,5-tri(octadecanoyloxy)oxan-2-yl]oxy-3,4-di(octadecanoyloxy)-5-(octadecanoyloxymethyl)oxolan-2-yl]methyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H]1[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@@H](CO)O1 WKTGPVRCJVGUCH-MYELPBIZSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 235000014541 cooking fats Nutrition 0.000 description 2
- 239000008162 cooking oil Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 2
- DNVPQKQSNYMLRS-APGDWVJJSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000010382 gamma-tocopherol Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 2
- 229940073769 methyl oleate Drugs 0.000 description 2
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- BTAXGNQLYFDKEF-UHFFFAOYSA-N propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCC BTAXGNQLYFDKEF-UHFFFAOYSA-N 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 150000003772 α-tocopherols Chemical class 0.000 description 2
- 235000007680 β-tocopherol Nutrition 0.000 description 2
- 150000003781 β-tocopherols Chemical class 0.000 description 2
- 150000003785 γ-tocopherols Chemical class 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- 150000003789 δ-tocopherols Chemical class 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- RKZXQQPEDGMHBJ-LIGJGSPWSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentakis[[(z)-octadec-9-enoyl]oxy]hexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC RKZXQQPEDGMHBJ-LIGJGSPWSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 125000003910 behenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002523 retinol group Chemical group 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 150000004370 vitamin A ester derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicinal Preparation (AREA)
Description
The present invention relates to certain edible, but non-absarbable and non-digestibla, liquid polyesters which can be used as low calorie fat substitutes in foods and as pharmaceutical compositions.
. The polyesters herein interfere with ths body's absorption of cholesterol and thereby provide c siaans fcr treating hypercholesterolemia. The polyesters can undesirably interfere with the body's, source of fatsoluble vitamins,, but in a preferred execution this . problem is overcome by fortification with vitamins.
It has been determined that the liquid polyesters herein can also cause an undesired anal leakage effect. Sy the present invention, certain agents are added. to the polyester compositions to avoid this undesired effect.
Preferred compositions for treating hypercholesterolemia and/or hyperlipidemia comprising the polyesters and antianal leakage agent are provided. Highly preferred compositions for treating hypercholesterolemia and/or hyperlipidemia comprising the polyesters, an anti-anal leakage agent, and one or more fat-soluble vitamins are provided.
High blood cholesterol (hypercholesterolemia) is. recognized as being a risk factor in cardiovascular disease which comprises a major health care, problem today. Epidemiological studies have demonstrated that,
- 3 with few exceptions, populations consuming large quantities of saturated fat and cholesterol have a relatively high concentration of serum cholesterol and a high mortality rate from coronary heart disease. While it is recognized that other factors can also contribute to the development of cardiovascular disease, there appears to be a causal relationship between the concentration of serum cholesterol, in which hypercholesterolemia results in the accumulation of undesirable amounts of cholesterol in various parts of the circulatory system (atherosclerosis) or in soft tissues (xanthomatosis), and coronary disease and coronary mortality rates.
A variety of dietary and drug regimens have been suggested for alleviating or preventing hypercholesterolemia.
By providing a fat substitute which is nonabsorbable and non-digestible, the total content of cholesterol in the body can be lowered. Mineral oil is a well-known laxative and has been suggested for use as a fat substitute and as a kind of intestinal solvent to dissolve cholesterol and cause its removal in body wastes. However, mineral oil has never been accepted for these uses. Moreover, mineral oil is partially absorbed by the body and undesirably deposits in the liver.
In the present invention, liquid, non-absorbable, non-digestible polyesters of sugars (or sugar alcohols) are used as fat substitutes in foods and, conveniently, in unit dose forms as therapeutic compositions. The polyesters herein are fat-like in their physical properties and are excellent fat substitutes for use in low calorie foods and diets. Moreover, the polyesters herein efficiently inhibit absorption of cholesterol by the body and in contrast with mineral oil, are not
4458
- 4 absorbed and/or deposited in the liver during usage in a treatment/prevention regimen with persons having or likely to develop hypercholesterolemia.
The anal leakage effect of the liquid polyesters of the type disclosed herein can be overcome by adding an anti-anal leakage agent of the type disclosed hereinafter to the liquid polyesters, or to foods containing same.
U.S. Patent 3,600,186 (1971) to Mattson and Volpenhein discloses low calorie food compositions containing polyol polyesters of the general type employed herein, and their use in combination with hardstocks which are fatty acid sources. The anti-anal leakage effect of fatty acids is not noted.
Patent Specification No. 40307 discloses and claims sugar polyesters of the general type employed herein for the treatment and/or prevention of hypercholesterolemia. A variety of optional carriers are mentioned, including the fatty acid, stearic acid. The anti-anal leakage effect of stearic acid is not mentioned.
U.S. Patent 1,656,474 (1928) to Dubin discloses edible fat compositions consisting of ethyl and glycerol esters of odd chain fatty acids in combination with fat-soluble vitamins,
Mattson and Molen, The Journal of Nutrition Vol, 102, No. 9, Sept. 1972, at pages 1171-1175, report on the lack of absorbability of sugar polyesters of the general type employed herein in rats.
Fallet, Glueck, Mattson and Lutmer, Clinical Research XXIII No. 3, page 319A (1975) report the lowering of both serum cholesterol and vitamin A and E levels in subjects receiving sugar polyesters of the present type.
U.S. Patent 2,962,419 (I960) to Minich relates
- 5 to neopentyl fatty esters and their use as fat substitutes.
U.S. Patent 3,160,565 (1964) to Η. E. Duell relates to sugar mono-, di- and tri-esters and their use as carriers for various orally-administered medicinals.
U.S. Patent 3,849,554 (1974) to Winitz discloses means for reducing blood serum cholesterol by ingesting diets comprising a fatty acid source, said diets being low in sucrose.
U.S. Patent 2,893,990 (1959) to Haas, et al., discloses fatty acid mono- and di-esters of sucrose which aid in the absorption of fat from the digestive tract.
U.S. Patent 3,158,490 (1964) to Baur and Lutton discloses non-cloudy salad oils containing esters of di-saccharides in which there are not more than five un-esterified hydroxy groups. See also U.S. Patents 3,059,009 (1962) and 3,059,010 (1962) to Schmid and Baur.
U.S. Patent 2,997,492 (1961) to Martin is directed to a method of making partial fatty acid esters of hexitols. U.S. Patent 2,997,491 (1961) to Huber is directed to the synthesis of partial fatty esters of inositol. The general methods of synthesis disclosed in these patents can be used to prepare the liquid polyesters herein. Preferred methods of synthesis are fully disclosed hereinafter.
In addition to the foregoing, there are other patents directed to the use of fat-soluble vitamins in a variety of naturally-occurring oils not contemplated by the present invention. See, for example, U.S.
Patent 2,685,517, issued August 3, 1954, to Nutrition Products, Inc.
} 4 4 5 8
- 6 Administration of anti-hypercholesterolemic amounts of a composition comprising a liquid polyester of the type described herein to an animal (especially humans) afflicted with or susceptible to hypercholesterolemia is an effective means of controlling the body's cholesterol level. Unfortunately, administration of cholesterol-controlling amounts of the liquid polyesters can result in an undesired laxative effect, namely, leakage of the liquid polyester through the anal sphincter. By combining the polyester compositions with an anti-laxative agent, especially an edible source of a C^2, or higher, saturated fatty acid, which provides such fatty acids in the gut, this undesired laxative effect is prevented. (By anti-anal leakage agent, or AAL agent, herein is meant those materials which prevent frank leakage of the liquid polyesters. The natural stool-softening effect of the polyesters is not substantially affected, nor is it a problem).
The present invention provides an antihypercholesterolemia and/or anti-hyperlipidemia composition comprising:
(a) an edible, non-absorbable, non-digestible polyol fatty acid polyester which is liquid (as hereinafter defined) and whioh has at least 4 fatty acid ester groups, wherein the polyol is selected from the group consisting of sugars and sugar alcohols, containing from 4 to 8 hydroxyl groups and wherein each fatty acid group has from about 8 to about 22 carbon atoms; and (b) sufficient anti-anal leakage agent to prevent leakage of said liquid polyester through the anal sphincter, the anti-anal leakage agent being selected from edible, digestible sources of C^2 and higher saturated fatty acids (other than the acid per se); edible non-absorbable, non-digestible solid polyol fatty acid polyesters having at least 4 fatty acid ester groups,
- 7 wherein the polyol is selected from the group consisting of sugars and sugar alcohols containing from 4 to 8 hydroxyl groups and wherein each fatty acid group has from about 8 to about 22 carbon atoms; and edible, non-digestible esters of alpha-branched chain cioC·^ fatty acids, and mixtures thereof.
Preferred executions of the invention herein further comprise sufficient fat-soluble vitamins selected from the groups consisting of vitamin A, vitamin
D, vitamin E and vitamin K, or mixtures thereof, to prevent abnormally low tissue levels of any said fatsoluble vitamins in animals ingesting said compositions.
The present invention also encompasses nonlaxative pharmaceutical compositions in effective unit dosage amounts for inhibiting the absorption of cholesterol, said compositions comprising from 0.1 gram to 5 grams, preferably from 1 gram to 5 grams of the liquid polyesters herein and sufficient AAL agent, especially an edible source of a C12, or higher, saturated fatty acid to prevent anal leakage in humans ingesting said compositions. Preferably, the compositions also comprise the fat-soluble vitamins.
The polyester materials herein are non-absorbable and non-digestible fat-like materials and are suitable for use as fat substitutes in low calorie fat-containing food compositions. Accordingly, the present invention also encompasses low calorie fat-containing food compositions comprising non-fat ingredients and fat ingredients wherein from about 10% to about 100% of the total fat ingredients comprise the liquid, non-absorbable, non-digestible polyesters of the type disclosed hereinafter, said compositions also containing an effective amount of an AAL agent, especially an edible source of a C12, or higher, saturated fatty acid which prevents an undesirable anal leakage effect. Preferred
4 4 5 8
- 8 executions of the low calorie fat-containing food compositions herein further comprise sufficient fatsoluble vitamins, or mixtures thereof, over and above that naturally present in said food compositions, to prevent abnormally low levels of any said fat-soluble vitamins in humans ingesting said compositions.
The present invention also encompasses methods for inhibiting the absorption of cholesterol without causing an anal leakage effect, comprising systemically (generally, orally) administering to animals susceptible to or afflicted with hypercholesterolemia successive therapeutically effective doses of the composition of the foregoing type.
The present invention also emcompasses methods for inhibiting the absorption of cholesterol without decreasing the tissues' supply of fat-soluble vitamins or causing an anal leakage effect comprising administering (generally, orally) to non-human animals susceptible to or afflicted with hypercholesterolemia successive therapeutically effective doses of the compositions of the foregoing type fortified with fat-soluble vitamins.
It is to be understood that the edible, nonabsorbable, non-digestible polyester materials herein are liquids at body temperature, i.e., having a melting point of ca. 37°C or below. (Edible, non-absorbable, non-digestible polyester materials that are solid at body temperature do not exhibit the undesirable anal leakage effects noted with the liquid polyesters. Indeed, such solid polyesters can be used as ene type of AAL agent herein). In general, the liquid polyesters are those which are made from unsaturated fatty acids, whereas the solid polyesters are substantially saturated.
The consumption of diets containing sucrose polyesters (SPE) has been shown to result in the desirable decrease in absorption of dietary cholesterol
4458
- 9 in animals; see Mattson, Jandaoek and Glueck, Clinical Research 23 445A (1975). Similar results have been noted in humans.
In studies of the foregoing type, rats which ingested about 300 mg. to about 3000 mg. total liguid polyester per day and human volunteers who ingested from about 10 grams to about 50 grams total liguid polyester per day exhibited anal leakage of the polyesters . Further studies indicated that this anal leakage effect was a direct result of the passage cf the polyesters through the anal sphincter. Briefly, this undesired effect is not unlike the effect which can be caused by the ingestion of excessive amounts of mineral oil. It has now been determined that this undesirable effect can be obviated by combining the liquid polyester compositions with certain AAL agents.
The following is a brief description of animal studies whereby the effect of the ingestion of the nonabsorbable, non-digestible sucrose polyesters herein on vitamin A (an oil-soluble vitamin) uptake in rats was first determined.
In general terms, the animal studies involved feeding groups of rats a vitamin A-free diet for seven days. During this time, the animals were fed either cottonseed oil (CSO) or SPE, or mixtures of the two, as the sole source of fats in the diet. (The SPE is described in more detail hereinafter).
After the initial seven-day period, the diets of the animals were supplemented with vitamin A. Following the seven days on the diets containing vitamin A, the animals were sacrificed and their livers were removed and analyzed for vitamin A content by the CarrPrice method, using the procedure of Ames, Risley and Harris.
In studies of the foregoing type the marked
- 10 differences of the response of the animals to the type of dietary fat ingested was unequivocal. Thus, when the dietary fat was CSO, over 70S of the vitamin A that was consumed was stored in the liver. The complete replacement of the normal dietary fats with SPE resulted in the storage of less than IOS of the vitamin A that was consumed.
In light of studies of the foregoing type, it is possible to provide a picture of the effect of SPE on fat-soluble vitamin (and cholesterol) uptake by the individual. Under usual dietary conditions (i.e., when ingesting ordinary absorbable, digestible oils or fats such as CSO), vitamin A, like cholesterol, initially is dissolved in an oil phase of triglycerides in the lumen of the intestinal tract. A portion of the triglycerides is hydrolyzed to monoglycerides and free fatty acids which, together with bile salts, form a micellar phase. Vitamin A is then distributed between the oil phase of unhydrolyzed triglyceride and the micellar phase. The proportion of vitamin A in each will be a function of the volume of each phase and the distribution coefficient of the vitamin. Eventually, almost all of the triglycerides are hydrolyzed and a major portion of the vitamin is absorbed.
In contrast, SPE and triglycerides are miscible. When both are present, a single oil phase is formed.
The digestion products of the triglycerides enter the micellar phase but SPE, because it is not hydrolyzed, remains as an oil phase. A significant portion of the ingested vitamin A (and cholesterol) remains in this SPE oil phase, the amount again depending on the volume coefficient of the vitamin. When the SPE is discharged, unchanged, in the stools, the oil-soluble viramin A dissolved in the SPE is also lost. A similar sequence of events presumably occurs also in the case of vitamin
4 4 5 8
- 11 E and also with the other fat-soluble vitamins, D and K.
As can be seen from the foregoing, the physicochemical properties which make the SPE so useful in preventing uptake of cholesterol by the body are the selfsame properties which undesirably interfere with uptake of fat-soluble vitamins.
This type of interference with the absorption of vitamins A and E has been demonstrated in human volunteers who consumed SPE. The consequence of SPE Ingestion was a drop in the blood (plasma) levels of these vitamins.
By the present invention SPE-type polyesters are fortified with fat-soluble vitamins, especially vitamin A, vitamin E and vitamin D, and mixtures thereof. (The polyesters can also be fortified with vitamin K. However, since the body can synthesize vitamin X, supplementation of the polyesters therewith is probably not critical to adequate nutrition in the normal subject). The vitaminfortified polyesters are used as fat substitutes in foods, in unit dose forms as pharmaceutical compositions, or are provided in bulk form for self-administration in a therapeutic or dietetic regimen.
The types of AAL agents which can be used herein to overcome the above-described anal leakage problem without interfering with the beneficial effects of the present compositions are disclosed immediately hereinafter.
Anti-Anal Leakage Agents
One class of materials which provide the antianal leakage effect herein includes edible, digestible sources of saturated fatty acids having a melting point of ca, 37°C, or higher; the acids in question, are 2 and higher saturated fatty acids, for example, the C'2-C24 saturated fatty acids.
4 5 8
- 12 While not intending to be limited by theory, it appears that the foregoing type of AAL agent functions via the formation of calcium or magnesium fatty acid soaps in the gut. These soaps apparently interact with the liquid polyesters herein and impart a stiffening effect thereto. Once stiffened, or partly solidified, in the gut, the polyesters do not leak through the anal sphincter. The antihypercholesterolemic effect of the liquid polyesters is not diminished.
Non-limiting examples of sources of the saturated fatty acids which can be used as the AAL agent herein include compounds such as. esters (e.g., triglycerides) that yield such saturated fatty acids on hydrolysis in the gut, soaps of the fatty acids such as the sodium, potassium, etc., water-soluble soaps, as well as the calcium and magnesium water-insoluble soaps.
Highly preferred herein for their anti-anal leakage effect are sources of the Cig-C22' roost preferably
C-jg-C-,θ, saturated fatty acids.
Specific examples of materials useful as the foregoing type of AAL agent herein include natural or processed fats yielding C]_2-C24' saturated fatty acids in the gut, e.g., materials such as cocoa butter, palm oil, palm kernel oil, coconut oil, tallow, lard, enriched concentrates of triglycerides having high levels of saturated fatty acids obtainable from these sources and sources such as highly saturated cottonseed oil fractions obtained by processes such as crystallization or directed rearrangement which yield the desired higher concentrations of the more saturated fatty acids in the resulting hardstook fractions. Such materials are all available by well-known processes.
Partially hydrogenated oils, including all of the above, as well as partially hydrogenated soybean oil, safflower seed oil, rapeseed oil, or such materials which are hydrogenated and concentrated, fc-r example by crystallization, to provide fractions which are enriched in sources of the longer-chain, substantially saturated fatty acids, are all useful as the AAL agent herein, (By substantially hydrogenated herein is meant oils having an iodine value of ca. 50, or lower.)
Of course, any of the foregoing unsaturated oils are useful herein after they have been substantially completely hydrogenated to convert the unsaturated fatty acid (ester) groups to the corresponding saturated fatty acids.
Synthetic materials, especially fatty acid esters made from the C^2~C24' more preferably C^g-C22> most preferably cpgcpg, saturated fatty acids are useful herein. Such materials include the esters of tetrahydric alcohols such as erythritol, esters of pentahydric alcohols such as xylitol, and esters of hexahydric alcohols such as sorbitol, and the like.
The C^2-C2^ saturated fatty acid esters of ci-c6 alcohols, for example monohydric alcohols such as methyl, ethyl and propyl alcohols (preferably ethyl alcohol) are also useful herein. Esters of dihydric alcohols such as 1,2-propanediol, and 1,3-butanediol, can also be used.
Highly preferred AAL agents herein which yield the foregoing fatty acids on hydrolysis in the gut are those which, in combination with the liquid polyesters herein, provide compositions having aesthetically pleasing organoleptic qualities, i.e., better mouth feel. Such aesthetically pleasing materials include naturally occurring cocoa butter and various synthetic cocoa and confectioners' butters. These preferred AAL agents include, for example, the so-called positionspecific triglycerides such as 1-stearoyl diolein (S00); 2-oleoyl-l, 3-distearin (SOS); or the
4 4 5 8 corresponding compounds wherein the stearoyl group is replaced by palmitoyl, arachidoyl or behenoyl groups. Another class of aesthetically preferred anti-laxative agents herein are 1-oleoyl distearin (OSS), 1-palmitoyl distearin (PSS), 1-arachidoyl distearin (ASS) and 1-behenoyl distearin (BSS).
These highly preferred, position-specific triglycerides which can be used as a fatty acid sourcetype of AAL agent herein can be prepared according to the methods described in U.S. Patent 3,809,711, Yetter, issued May 7, 1974.
As noted hereinabove, the foregoing types of AAL agents appear to function by providing a saturated fatty acid in the gut, said fatty acid thereafter presumably forming an insoluble calcium or magnesium soap in situ. This soap then appears to provide the stiffening effect on the liquid polyester, thereby preventing the undesirable anal leakage effect. As noted hereinabove, the solid polyester materials of the present type (i.e., solid, edible, but nondigestible, non-absorbable polyesters) do not cause the undesirable anal leakage effect. It has been determined that these solid polyester materials can also be used as an AAL agent and these represent a second class of AAL agents herein. Since these solid polyester materials do not hydrolyze in the gut to form free fatty acids, or calcium or magnesium fatty acid soaps, their anti-anal leakage effect must be the result of a different mechanism from that which operates with the hydrolyzable esters and fatty acid sources described immediately hereinabove. Presumably, the combination of the solid polyester with the liquid polyesters simply provides a stiffening effect due to some type of crystallization or phase change within the gut.
It will be appreciated that by combining liquid
4 4 5 8
- 15 and solid non-absorbable, non-digestible polyesters to provide the desired anti-anal leakage effect, wholly edible, but non-digestible, non-absorbable, non-caloric compositions are secured. These compositions are quite effective in the treatment of hypercholesterolemia and in low calorie diets.
Typical examples of solid, non-absorbable, nondigestible polyester AAL agents herein include sucrose cctastearate, sucrose octapalmitate, sucrose heptastearate, xylitol pentastearate, galactose pentapalmitate, and like saturated polyol polyesters having at least four -OH groups esterified with saturatei^ fatty acids.
Another type of AAL agent herein comprises fatty acid esters which are ncn-digestible by virtue of branching on the σ-carbon atom of the fatty acid moiety. Such materials, which are well known in the chemical arts, include, for example, σ-methyi and a, «-dimethyl Cl0~Cl8 fatfcy esters of lower alcohols such as ethanol and of polyols such as glycerol.
Liquid Polyesters
The liquid polyol polyesters (or, simply, polyesters) employed in this invention comprise certain polyols, especially sugars or sugar alcohols, esterified with at least four fatty acid groups. Accordingly, the polyol starting material must have at least four esterifiable hydroxyl groups. Examples of preferred polyols are sugars, including monosaccharides and disaccharides, and sugar alcohols. Examples of monosaccharides containing four hydroxyl groups are xylose and arabinose and the sugar alcohol derived from xylose, which has five hydoxyl groups, i.e., xylitol. (The monosaccharide, erythrose, is not suitable in the practice of this invention since it only contains three hydroxyl groups, but the sugar alcohol derived from erythrose, i.e. erythritol, contains four hydroxyl groups and
4 4 5 8
- 16 accordingly can be used). Suitable five hydroxyl groupcontaining monosaccharides are galatose, fructose, and sorbose. Sugar alcohols containing six-OH groups derived from the hydrolysis products of sucrose, as well as glucose and sorbose, e.g., sorbitol, are also suitable. Examples of disaccharide polyols which can be used include maltose, lactose, and sucrose, all of which contain eight hydroxyl groups.
Preferred polyols for preparing the . polyesters for use in the present invention are selected from the group consisting of erythritol, xylitol, sorbitol, glucose and sucrose. Sucrose is especially preferred.
The polyol starting material having at least four hydroxyl groups must be esterified on at least four of the -OH groups with a fatty acid containing from about 8 to about 22 carbon atoms. Examples of such fatty acids include caprylic, capric, lauric, myristic, myristoleic, palmitic, palmitoleric, stearic, oleic, ricinoleic, linoleic, linolenic, eleostearic, arachldic, arachidonic, behenie, and erucic acid. The fatty acids can be derived from naturally occurring or synthetic fatty acids; they can be saturated or unsaturated, including positional and geometrical isomers. However, in order to provide liquid polyesters of the type used herein, at least about half, of the fatty acid incorporated into the polyester molecule must be unsaturated.
Oleic and linoleic acids, and mixtures thereof, are especially preferred.
The liquid polyol fatty acid polyesters useful in this invention must contain at least four fatty acid ester groups. Polyol fatty acid polyester compounds that contain three or less fatty aoid ester groups are digested in and the products of digestion are absorbed from the intestinal tract much in the manner of ordinary triglyceride fats, whereas the polyol fatty acid
4 4 5 8
- 17 polyester compounds that contain four or more fatty acid ester groups are substantially non-digestible and consequently non-absorbable by the human body.
It is not necessary that all of the hydroxyl groups of the polyol be esterified with fatty acid, but it is preferable that the polyester contain no more than two unesterified hydroxyl groups. Most preferably, substantially all of the hydroxyl groups of the polyol are esterified with fatty acid, i.e., the compound is substantially completely esterified. The fatty acids esterified to the polyol molecule can be the same or mixed (but, as noted above, a substantial amount of the unsaturated acid ester groups must be present to provide liquidity).
To illustrate the above points, a sucrose fatty triester would not be suitable for use herein because it does not contain the required four fatty acid ester groups. A sucrose tetra-fatty acid ester would be suitable, but is not preferred because it has more than two unesterified hydroxyl groups. A sucrose hexa-fatty acid ester would be preferred because it has no more than two unesterified hydroxyl groups. Highly preferred compounds in which all the hydroxyl groups are esterified with fatty acid include the liquid sucrose octa-fatty acid esters.
The following are non-limiting examples of specific liquid polyol fatty acid polyesters containing at least four fatty acid ester groups suitable for use in the present inventions glucose tetraoleate, the glucose tetraesters of soybean oil fatty acids (unsaturated) , the mannose tetraesters of mixed soybean oil fatty acids, the galactose tetraesters of oleic acid, the arabinose tetraesters of linoleic acid, xylose tetralinoleate, galactose pentaoleate, sorbitol tetraoleate, the sorbitol hexaesters of unsaturated soybean oil fatty acids, xylitol pentaoleate, sucrose tetraoleate,
4.4 S 8
- 18 sucrose pentaoleate, sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate, and mixtures thereof.
As noted above, highly preferred polyol fatty acid esters are those wherein the fatty acids contain from about 14 to about 18 carbon atoms.
The polyol fatty acid polyesters suitable for use herein can be prepared by a variety of methods well known to those skilled in the art. These methods include: transesterification of the polyol with methyl, ethyl or glycerol fatty acid esters using a variety of catalysts; acylation of the polyol with a fatty acid chloride; acylation of the polyol with a fatty acid anhydride? and acylation of the polyol with a fatty acid, per se. As an example, the preparation of polyol fatty acid esters is described in U.S. Patent 2,831,854.
Specific, but non-limiting, examples of the preparation of polyol fatty acid esters suitable for use in the practice of this invention are as follows.
Erythritol tetraoleate - Erythritol and a five20 fold molar excess of methyl oleate are heated at 180°C, under vacuum, with agitation, in the presence of sodium methoxide catalyst over two reaction periods of several hours each. The reaction product (predominantly erythritol tetraoleate) is refined in petroleum ether and crystallized three times from several volumes of acetone at 1°C.
Xylitol pentaoleate - Xylitol and five-fold molar excess of methyl oleate in diamethylacetamide (DMAC) solution are heated at 180°C for five hours in the presence of sodium methoxide catalyst, under vacuum. During this time the DMAC is removed by distillation.
The product (predominantly xylitol pentaoleate) is refined in petroleum ether solution and, after being freed of petroleum ether, is separated as a liquid layer four times from acetone at ca. 1°C and twice from alcohol
- 19 at ca. 10°C.
Sorbitol hexaoleate is prepared by essentially the same procedure used to prepare xylitol pentaoleate except that sorbitol is substituted for xylitol.
Sucrose octaoleate is prepared by substantially the same procedure as that used to prepare erythritol tetraoleate except that sucrose is substituted for erythritol.
Vitamins
The vitamins used to fortify the foregoing polyesters in the preferred execution of the invention herein are described in detail hereinafter. It will be appreciated that commercial preparations of the appropriate vitamins and/or appropriate vitamin mixtures which provide vitamins A, D, E and K can be used herein.
In general terms, the vitamins are classified as either fat-soluble or water-soluble. The fatsoluble vitamins are used to fortify the polyester materials herein. The fat-soluble vitamins include vitamin A, vitamin D, vitamin E, and vitamin K.
Vitamin A (retinol) can be used to fortify the polyesters herein. Vitamin A is a fat-soluble alcohol of the formula H2g OH. Natural vitamin A is usually found esterified with a fatty acid; metabolically active forms of vitamin A also include the corresponding aldehyde and acid. All such fat-soluble forms of vitamin A (including the carotenoids) are contemplated for use in the present invention and are considered to be encompassed by the term vitamin A as used herein. The role of vitamin A in normal human metabolism has not been established with certainty, but it is known that this vitamin is essential to proper vision.
Vitamin D (calciferol) can be used to fortify the polyesters herein. Vitamin D is a fat-soluble vitamin •ΐ 4 4 5 8
- 20 well known for use in the treatment and prevention of rickets and other skeletal disorders. Vitamin D comprises sterols, and there are at least 11 sterols with vitamin D-type activity. Of these, only those known as and Dg are of substantial practical importance. Ergosterol, a plant sterol closely related to cholesterol in structure, is known as provitamin D2 and 7-dehydrQcholesterol is known as provitamin Og. Each of these provitamins is converted to the corresponding active form by irradiation with ultra-violet light. Ergocalciferol (D2) is prepared commercially for use as a vitamin supplement. Cholecalciferol (Dg) is a form synthesized in animal tissues and is chiefly found in the natural fish oils. The present invention fully contemplates the use of any of the vitamins and provisions having vitamin D-type activity and the term vitamin D” as used herein is intended to encompass all such fat-soluble materials.
Vitamin E (tocopherol) is a third fat-soluble vitamin which can be used in the present invention. Four different tocopherols have been identified (alpha, beta, gamma and delta), all of which are oily, yellow liquids, insoluble in water but soluble in fats and oils. Of the four tocopherols, alpha is the most active biologically, a factor which may be related to better absorption from the intestine. Delta tocopherol is the most potent antioxidant of the four. It has been suggested that-vitamin E deficiency may cause a variety of symptoms such as fetal abnormalities and deaths, myocardial degeneration, and necrosis of the liver, but the role of this vitamin in human nutrition is not yet well established. The term vitamin Ξ as employed herein is intended to encompass all the fat-soluble tocopherols having vitamin E-type activity.
Vitamin K exists in at least three forms, all belonging to the group of chemical compounds known as
4 4 5 S
- 21 quinones. The naturally-occurring fat-soluble vitamins are Kj (phylloquinone), K2 (menaquinone) and K^ (menadione). Vitamin K deficiency usually results in poor clotting of the blood, among other symptoms. The term vitamin K as employed herein is intended to include all the foregoing fat-soluble quinones having vitamin K-type activity.
From the foregoing it is to be understood that vitamins A, D, E and K, the corresponding provitamins and derivations thereof, such as esters, having vitamin A, Ij, E or K-type activity in animals, especially humans, are fully contemplated for use herein and are encompassed by the term vitamin as used herein.
The amount of the individual fat-soluble vitamins used to fortify the present compositions can vary with the age of the recipient, the dosage regimen used, and the amount of the vitamin ingested from other dietary sources. For example, in younger, growing children or in pregnant females it is recognized that larger amounts of any given vitamin should be ingested to supply optimal nutritional benefits than are needed with adult males. If the user of the present compositions happens to ingest foods which are extremely rich in a given fatsoluble vitamin, less of that vitamin need be used in the present compositions to insure adequate intestinal uptake for good nutrition. In any event, an attending physician can, if so desired, measure the amount of fatsoluble vitamins in the plasma. Based on these data, the appropriate type and amount of fat-soluble vitamin used to fortify the polyesters herein can then be determined on an individual basis.
More simply, the formulator of the compositions herein can fortify the polyesters with a recommended daily allowance (RDA), or increment or multiple of an RDA, of any of the fat-soluble vitamins to insure
4 4 5 8
- 22 that the user of the compositions will maintain a nutritionally adequate uptake of said vitamins. For example, with vitamin A a daily amount in the range of 20 international units (I.U.) to about 57 I.U. per kilogram of body weight can be employed. With vitamin D, fortification of the compositions to provide about 400 I.U., total, per day is ample. When supplementing with vitamin E, the amount of the vitamin optimal for dietary intake ranges from 3-6 I.U. for infants to 25-30 I.U., total, per day, for adults. When supplementing with vitamin K, it is more difficult to estimate the amount to be ingested to provide adequate nutrition since the microorganisms living in the intestine can synthesize this vitamin. However, it is known that ingestion of from 0.5 mg.-l mg. of vitamin K per day will prevent insufficiency.
As can be seen from the foregoing, the amount of the fat-soluble vitamins employed herein to fortify the polyesters can vary. In general, the polyesters are fortified with sufficient fat-soluble vitamin to provide from about 0.08% to about 150% of the average RDA. A preferred composition of the invention comprises from 50% to 90% by weight of the liquid polyol fatty acid polyester, at least 9.999% by weight of the anti-anal leakage agent, and from 0.001% to 2% by weight of the vitamin.
In therapeutic regimens the dosage of the compositions herein can vary with the severity of the hypercholesterolemia condition and the duration of the treatment. Individual dosages can range from about 0.01 mg/kg. to about 500 mg/kg., and greater (unless otherwise specified, the unit designated mg./kg. as used herein refers to mg. of liquid polyester per kilogram, of body weight), preferably from about 0.1 mg./kg. to about 125 mg./kg. per dosage, with up to six dosages, preferably three dosages, being given daily, most prefer4 4 4 5 8 ably at meal times. Because of the AAL agent, such high dosages can be administered without fear of producing anal leakage effects. Dosages of less than about 0.1 mg./kg. do not materially inhibit the absorption of cholesterol in most patients. The dosages can be administered orally in any suitable unit dosage form such as pills, tablets, and capsules. Preferred are capsules made from gelatin. The dosages can also be administered as part of a controlled dietary regimen, e.g., as a synthetic salad oil or cooking oil or fat.
The pharmaceutical compositions herein can comprise the polyester/AAL agent with or without fortifying fat-soluble vitamins alone, or in combination with any desired, non-interfering pharmaceutical carrier. As used herein, the term pharmaceutical carrier means a solid or liquid filler, diluent or encapsulating substance. Some examples of the substances which can serve as pharmaceutical carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium earboxymethylcellulose, ethyloellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and soybean oil; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar; alginic acid; pyrogen-free water; isotonic saline; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents and preservatives can also be present in the compositions, according to the desires of the formulator.
The pharmaceutical carriers of the foregoing type can optionally be employed in conjunction with the liquid polyesters herein to provide a practical size to
4 4 5 8
- 24 dosage relationship, composition forms which can be easily ingested, and means for providing accurate unit dosages in a convenient form. The pharmaceutical carrier usually will comprise from about 5% to about 50% by weight of the total pharmaceutical composition.
Since the liquid polyesters of the present compositions are not unlike cooking and salad oils and fats in their physical properties, the present compositions can be used as a partial or total replacement for normal triglyceride fats in any fat-containing food composition to provide anti-hypercholesterolemic and low calorie benefits. In order to achieve these benefits in a reasonable time, it is necessary that at least about 10¾ of the fat in the food composition comprises the polyesters herein. Highly desirable food compositions are those wherein the fatty component comprises up to about 100S of the polyester/anti-anal leakage compositions herein. Accordingly, the compositions of this invention can be used as a partial or complete replacement for normal triglyceride fats in a salad or cooking oil, or in plastic shortenings for use in frying, cake making, bread making, and the like. The compositions can also be used as partial or complete replacements for normal triglyceride fats in fat-containing food products such as mayonaise, margarine, and dairy products.
Preferred fat-containing food compositions of the present type comprise non-fat ingredients and fat ingredients wherein from 10% to 100%, preferably from 10% to 95% of the total fat consists essentially of a liquid sugar fatty acid polyester having at least four fatty acid ester groups, each fatty acid having from about 8 to about 22 carbon atoms, said sugar fatty acid polyester and/or food composition made therefrom also comprising an AAL agent of the type disclosed herein and, preferably, being fortified with the fat-soluble vitamins. Such food compositions will most often contain at least
4 4 5 8
- 25 about 10%, generally 15% to 25% (by weight of liquid polyester) of a fatty acid source which provides the anti-anal leakage effect. Highly preferred are food compositions wherein the sugar fatty acid ester contains no more than two unesterified hydroxy groups. Liquid sucrose polyesters, especially those wherein the ester groups are mainly of the unsaturated type and contain 14 to 18 carbon atoms, when used in the manner of this invention, are especially preferred for use in such anti-hypercholesterolemic and low calorie food compositions.
The total AAL agent employed in any of the compositions and methods herein will depend somewhat on the total amount of liquid polyester being ingested per day. The anti-anal leakage agent should preferably be present in an amount equaling at least about 10% by weight of the liquid polyester. It is more preferred that the AAL agent comprises at least about 20% by weight of the liquid polyester to ensure that anal leakage does not occur, even at high ingestion rates. Compositions wherein the weight of AAL agent comprises from about 20% to about 50% of the weight of liquid polyester provide excellent control of serum cholesterol without anal leakage of the polyester.
Compositions comprising edible fatty acids, their edible salts or their edible, digestible esters wherein the weight of AAL agent comprises about 10% to about 50% by weight of these materials by weight of liquid polyester. Compositions using the palatable position-specific triglycerides as the AAL agent preferably comprise about 20% to about 40% (by weight of liquid polyester) of these AAL agents. When the edible, non-absorbable non-digestible solid polyesters are used as the AAL agent, they are preferably used at a rate of from about 20% to about 50% by weight of the liquid polyester.
The following, non-limiting examples illustrate the compositions and processes of this invention. It will
4 5 8
- 26 be appreciated that sugars and sugar alcohols, appropriately esterified, are encompassed by the term sugar as used herein and such materials can be inter-changed in the compositions.
EXAMPLE X.
Gelatin capsules for use by the hypercholesterolemic patient are prepared by conventional methods, as follows :
Ingredient Amount per Capsule
Sucrose polyester* 2000 mg.
Methyl Stearate 250 mg.
*Liquid, mixed hexa-, hepta- and oeta-sucrose esters, predominantly the octa-ester, esterified with mixed soybean oil fatty acids, predominantly in the C^g-Ο^θ chain length.
The capsules of the foregoing type are prepared by simply mixing the ingredients and filling the standard gelatin capsules. The capsules are administered orally three times daily (three times each meal). This treatment regimen inhibits cholesterol uptake significantly and decreases the serum cholesterol levels in the circulatory systems of humans with, or disposed towards, hypercholesterolemia. The patients are not troubled by undesired anal leakage with this regimen.
Similar results are obtained when the sucrose polyester in the capsules of Example I is replaced with an equivalent quantity of a fatty acid polyester selected from the group consisting Of glucose tetraoleate; glucose tetrastearate mixed glucose tetraesters of unsaturated soybean oil fatty acids; mixed mannose tetraesters of oleic acid; mixed galactose tetraesters of linoleic acid; mixed arabinose tetraesters of oleic aeid;
ι ι ft
- 27 xylose tetralinoleate; galactose pentaoleate; sorbitol tetraoleate; sucrose tetraoleate; sucrose pentaoleate; sucrose hexaoleate; sucrose heptaoleate; and sucrose octaoleate, respectively.
In the composition of Example I, the methyl stearate anti-anal leakage ingredient is replaced by an equivalent amount of propyl stearate, methyl behenate, ethyl behenate, substantially completely hydrogenated palm oil, hydrogenated rapeseed oil, and mixed hydrogenated tallow triglycerides, respectively, and equivalent results are secured.
Preferred pharmaceutical compositions of the type of Example I for inhibiting the absorption of cholesterol, especially in the human body, preferably comprise from about 0.1 gram to about 5 grams of the liquid polyester and an effective amount (as disclosed hereinabove) of the ZiAL agent.
EXAMPLE II.
Gelatin capsules for use by the hypercholesterolemic patient are prepared by conventional methods, as follows:
Ingredient
Amount per Capsule
Sucrose polyester* Retinol
Methyl stearate
2000 mg. 0.3 RDA
750 mg.
*Liquid, mixed hexa-, hepta- and octa-sucrose esters, predominantly the octa-ester, esterified with mixed soybean oil fatty acids, predominantly in the c^gc]g chain length.
The capsules of the foregoing type are prepared by simply mixing the ingredients and filling the standard gelatin capsules. The capsules are administered orally
4 5 8
- 28 three times daily (three with each meal). This treatment regimen inhibits cholesterol uptake significantly and decreases the serum cholesterol levels in the circulatory systems of humans with, or disposed towards, hypercholesterolemia. Vitamin A levels in the patients are not decreased significantly from the normal. The patients are not troubled by undesired anal leakage with this regimen.
Similar results are obtained when the sucrose polyester in the capsules of Example II is replaced with an equivalent quantity of a fatty acid polyester selected from the group consisting of glucose tetraoleate? glucose tetrastearate; mixed glucose tetraesters of soybean oil fatty acids; mixed mannose tetraesters of tallow fatty acids; mixed galactose tetraesters of olive oil fatty acids; mixed arabinose tetraesters of cottonseed oil fatty acids? xylose tetra linoleate; galactose pentastearate? sorbitol tetraoleate? sucrose tetrastearate; sucrose penta20 stearate; sucrose hexaoleate? sucrose heptaoleate? and sucrose octaoleate respectively.
In the composition of Example II the retinol is replaced by an equivalent dosage level of a commercial vitamin A ester concentrate and equivalent results are secured.
In the composition of Example II, the methyl stearate anti-anal leakage ingredient is replaced by an equivalent amount of ethyl stearate, propyl stearate, methyl behenate, ethyl behenate, hydrogenated palm oil, hydrogenated rapeseed oil and mixed hydrogenated tallow triglycerides, respectively, and equivalent results are secured.
Preferred compositions of the type of Example II for inhibiting the absorption of cholesterol, especially in the human body, preferably comprise from about 0.1 gram to about 5 grams of the liquid polyester,
4 4 5 8
- 29 an effective amount (as disclosed hereinabove) of the AAL agent and at least about 0.1 RDA of one or more of the fat-soluble vitamins.
EXAMPLE III.
Gelatin capsules comprising a unit dose of an AAL agent and a liquid polyester are prepared by conventional means, as follows:
Ingredient Amount per Capsule
Sucrose octaoleate 3500 mg.
Hydrogenated palm oil 750 mg.
The above capsules are administered orally three times daily (three per meal/70 kg. man) over a one-month period. This treatment regimen substantially inhibits cholesterol uptake in the patient and decreases the serum level of cholesterol. No anal leakage from use of the capsules is noted.
The hydrogenated palm oil in Example III is replaced by an equivalent amount of tristearin and equivalent anti-anal leakage results are secured.
When oleic acid is used to replace the hydrogenated palm oil, no substantial anti-anal leakage effect is noted.
The above capsules are fortified with vitamin E which consists of mixed alpha, beta, gamma and delta tocopherols using 0.2 RDA of vitamin E per capsule.
The capsules are additionally fortified with sufficient β-carotene to provide a 0.25 RDA of vitamin A per capsule.
EXAMPLE IV.
Gelatin capsules comprising an AAL agent and a
- 30 4 4458 liquid polyester are as follows;
Ingredient
Mg. per Capsule
Sucrose octaoleate 2000
Ethyl stearate 250
Three capsules of the type prepared in Example
IV are administered orally five times daily (three capsules per occurrence) to inhibit cholesterol uptake and decrease the level of cholesterol in the circulatory system Of a 70 kg. patient afflicted with hypercholesterolemia. At these dosage levels, no anal leakage is noted. Similar dosages of the foregoing capsules without ethyl stearate cause an undesired leakage of sucrose octaoleate through the anal sphincter.
EXAMPLE V.
Gelatin capsules comprising an AAL agent, a liquid polyester and containing a mixture of the fatsoluble vitamins are as follows:
Ingredient
Mg. per Capsule
Sucrose ootaoleate 20 Vitamin A
Vitamin D Vitamin E Vitamin K Ethyl stearate
2000
0.1
0.01
0.1
0.1
750
The vitamin A employed in the capsules of
Example V is retinol; the vitamin D is a 1:1 mixture of irradiated ergosterol and irradiated 7-dehydrooholesterol; the vitamin E comprises a commercial mixture of alpha, beta, gamma and delta tocopherols; and the vitamin K comprises the fat-soluble phyllo4 4 4 5 8
- 31 qurnone.
Three capsules of the type prepared in Example V are administered orally five times daily (three with each meal) to inhibit cholesterol uptake and decrease the level of cholesterol in the circulatory system of a 70 kg. patient afflicted with hypercholesterolemia.
The body levels of fat-soluble vitamins A, D, E and K do not decrease below normal. No anal leakage is noted. Similar capsules in this dosage range without ethyl stearate cause an undesired laxative effect, i.e., leakage of polyester through the anal sphincter.
EXAMPLE VI.
A highly palatable, low calorie composition suitable for use by patients on anti-hypercholesterolemic therapeutic regimens and/or as a cooking fat substitute by individuals on an anti-hyperlipidemic diet is as follows:
Ingredient Liquid sucrose polyester* Cocoa butter % by Weight *Avg. 7.5 ester of sucrose and oleic acid.
The composition of the foregoing type is suitable for use in standard fashion as a low calorie cooking fat. No anal leakage of the liquid polyester is noted.
The composition of Example VI is ingested at a rate of 50 g./day (150 lb. patient) and reduces serum cholesterol without anal leakage of the liquid polyester
In the composition of Example VI the natural cocoa butter is replaced by an equivalent amount of the position-specific triglycerides SOO, SOS, OSS, PSS, ASS
Λ 4 4 5 8
- 32 and BSS, respectively, and equivalent compositions are secured.
In the compositions of Example VI the liquid sucrose polyester comprising average 7.5 ester of sucrose and unsaturated, mixed soybean oil fatty acids fortified to provide 1000 I.U. of vitamin A per ounce of composition. Equivalent results are obtained and no depletion of Vitamin A in the tissues is caused.
EXAMPLE VII.
A plastic shortening is prepared from the following ingredients.
Ingredient
Cocoa butter Liquid xylitol pentaoleate
OSS % by Weight
The composition of Example VII is prepared by thoroughly mixing the indicated ingredients. The composition is suitable for use in frying and other types of cooking where a plastic fat is employed. The fat composition of Example VII can also be employed in the preparation of baking doughs suitable for use by the hypercholesterol patient. Continued ingestion of the plastic shortening of Example VII, or foods made therefrom, reduces the body's serum cholesterol level Without anal leakage of the xylitol pentaoleate.
The shortening of Example VII can be used by the normal or hyperlipidemic patient to control body weight.
The composition of Example VII is fortified with sufficient irradiated ergosterol to provide 40.0
I.U. of vitamin D per two ounce serving. Equivalent
4 4 5 8
- 33 results are obtained and vitamin D deficiency does not result.
EXAMPLE VIII,
A non-anal leakage, low calorie, antihypercholesterolemic composition prepared with an edible, but non-absorbable, non-digestable, solid polyester AAL agent is as follows;
Ingredient % by Weight
Sucrose octaoleate 70
Sucrose octastearate 30
The composition of Example VIII is prepared by simply combining the ingredients. The composition is suitable for use by the hypercholesterolemic patient to reduce serum cholesterol levels; no anal leakage is noted.
The composition of Example VIII can be used by the normal or hyperlipidemic patient to control serum cholesterol without increasing calorie intake.
In the composition of Example VIII the sucrose octastearate is replaced by an equivalent amount of sucrose heptastearate, and sucrose octapalmitate, respectively, as the AAL agent and equivalent results are secured.
The composition of Example VIII is vitaminfortified with a commercial mixture of vitamins A, D, E and K sufficient to provide an RDA of each of these vitamins per three ounce serving.
Equivalent results are obtained while maintaining normal levels of the fat-soluble vitamins.
Claims (22)
1. An anti-hypercholesterolemia and/or antihyperlipidemia composition, comprising: (a) an edible non-absorbable, non-digestible polyol fatty acid polyester which is liquid (as hereinbefore defined) and which has at least 4 fatty acid ester groups, wherein the polyol is selected from the group consisting of sugars and sugar alcohols containing from 4 to 8 hydroxyl groups and wherein each fatty acid group has from about 8 to about 22 carbon atoms; and (b) sufficient anti-anal leakage agent to prevent leakage of said liquid polyester through the anal sphincter, the anti-anal leakage agent being selected from edible, digestible sources of C^ 2 and higher saturated fatty acids (other than the acids per se); edible, non-absorbable, non-digestible solid polyol fatty acid polyesters having at least 4 fatty acid ester groups, wherein the polyol is selected from the group consisting of sugars and sugar alcohols containing from 4 to 8 hydroxyl groups and wherein each fatty acid group has from about 8 to about 22 carbon atoms; and edible, non-digestible esters of alpha-branched chain C 1O -C 18 fatty acids, and mixtures thereof.
2. A composition according to claim 1 wherein the liquid polyol fatty acid polyester contains no more than about 2 free hydroxyl groups.
3. A composition according to claim 1 or claim 2 wherein the fatty acid ester groups of the liquid polyol polyester contain from about 14 to about 18 carbon atoms.
4. A composition according to any one of claims 1-3 wherein the polyol of the liquid polyol polyester is ί Ο Β 8 - 35 erythritol, xylitol, sorbitol, glucose or sucrose.
5. A composition according to claim 4 wherein the polyester is selected from the hexaoleate, heptaoleate and octaoleate of sucrose, and mixtures thereof.
6. A composition according to any one of claims 1-5 which comprises at least 10% of the antianal leakage agent, by weight of the liquid polyester.
7. A composition according to claim 6 which comprises from 20% to 50% of the anti-anal leakage agent, by weight of the liquid polyester.
8. A composition according to any one of claims 1-7 wherein the anti-anal leakage agent is selected from edible digestible sources of C^ 2 “ C 24 satu rated fatty acids.
9. A composition according to claim 8 wherein the anti-anal leakage agent is one or more C^-Cg alkyl esters of c i2~ C 24 satura ted fatty acids.
10. A composition according to claim 8 wherein the anti-anal leakage agent comprises one or more substantially saturated triglyceride esters of c y2~ C 24 fatty acids.
11. A composition according to claim 10 wherein the anti-anal leakage agent is hydrogenated palm oil.
12. A composition according to claim 10 wherein the anti-anal leakage agent is natural or synthetic cocoa butter.
13. A composition according to claim 10 wherein the anti-anal leakage agent is an edible position4 4 5 8 - 36 specific triglyceride selected from the group consisting of: the I-stearoyl, 1-palmitoyl, 1-arachidoyl and 1-behenoyl 2,3-dioleins; the 2-oleoyl 1,3-distearins, 1,3-dipalmitins, 1,3-diarachidins and 1,3-dibehenins; 1-oleoyl distearin; 1-palmitoyl distearin; 1-arachidoyl distearin; and 1-behenoyl distearin, and mixtures thereof.
14. A composition according to claims 1-7 wherein the anti-anal leakage saturated fatty acid polyol ester. any one of agent is C 1O “ C 22
15. A composition according to any one of claims 1-14 and additionally comprising sufficient fatsoluble vitamin selected from the group consisting of vitamin A, vitamin D, vitamin E, vitamin K and mixtures thereof to prevent abnormally lox·? levels of any of said fat-soluble vitamins in animals ingesting said composition.
16. A composition according to claim 15 which comprises from 50% to 90% by weight of the liquid polyol fatty acid polyester, at least 9,999% by weight of the anti-anal leakage agent, and from 0.001% to 2% by weight of the vitamin.
17. A lox·? calorie fat-containing food composition comprising non-fat ingredients and fat ingredients, wherein from 10% to 100% of the total fat ingredients is a composition according to any one of claims 1 to 16.
18. A pharmaceutical composition in effective unit dosage amounts for inhibiting the absorption of cholesterol without causing an anal leakage effect, comprising a composition as claimed in any one of claims 1-14 and in which the liquid polyol fatty acid polyester is present in an amount of from 0.1 gram to 5 grams. 4 4 4 5 8 - 37
19. A composition according to claim 18 which additionally comprises sufficient fat-soluble vitamin selected from the group consisting of vitamin A, vitamin D, vitamin E and vitamin K to prevent 5 abnormally low levels of any of said fat-soluble vitamins in animals ingesting said composition,
20. A composition according to claim 19 which contains at least about 0.1 RDA of vitamin.
21. A composition according to claim 1 10 substantially as hereinbefore described with reference to any one of the examples.
22. A method for inhibiting the absorption of cholesterol in non-human animals without causing an anal leakage effect comprising administering to a non15 human animal susceptible to or afflicted with hypercholesterolemia successive therapeutically effective doses of a composition as claimed in any one of claims 18-20.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/657,528 US4005195A (en) | 1976-02-12 | 1976-02-12 | Compositions for treating hypercholesterolemia |
| US05/657,529 US4005196A (en) | 1976-02-12 | 1976-02-12 | Vitaminized compositions for treating hypercholesterolemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE44458L IE44458L (en) | 1977-08-12 |
| IE44458B1 true IE44458B1 (en) | 1981-12-02 |
Family
ID=27097425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE213/77A IE44458B1 (en) | 1976-02-12 | 1977-02-02 | Compositions for treating hypercholesterolemia |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS52120131A (en) |
| DE (1) | DE2705105A1 (en) |
| FR (1) | FR2340737A1 (en) |
| GB (1) | GB1579241A (en) |
| IE (1) | IE44458B1 (en) |
| IT (1) | IT1075126B (en) |
| LU (1) | LU76751A1 (en) |
| NL (1) | NL188503C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4368213A (en) * | 1981-06-23 | 1983-01-11 | The Procter & Gamble Company | Emulsion concentrate for palatable polyester beverage |
| DE3788443T2 (en) * | 1986-02-20 | 1994-04-28 | Procter & Gamble | Low-calorie fat products that rule out the laxative side effects. |
| EP0233856B1 (en) * | 1986-02-20 | 1994-01-05 | The Procter & Gamble Company | Better tasting low calorie fat materials |
| US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
| JPH07108184B2 (en) * | 1987-11-25 | 1995-11-22 | 三菱化学株式会社 | Manufacturing method of chicorylate |
| US5006360B1 (en) * | 1988-06-27 | 1992-04-28 | Low calorie fat substitute compositions resistant to laxative side effect | |
| CA2004723C (en) * | 1988-12-22 | 1997-03-04 | James Anthony Letton | Fatty compositions with high solids content |
| EP2298293A1 (en) * | 2004-01-16 | 2011-03-23 | Fuji Oil Company, Limited | Lipase inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2997492A (en) * | 1959-02-17 | 1961-08-22 | Procter & Gamble | Method for preparing fatty esters of straight chain hexitols |
| US2997491A (en) * | 1959-09-29 | 1961-08-22 | Procter & Gamble | Method for preparing partial fatty esters of inositol |
| US3059009A (en) * | 1961-09-21 | 1962-10-16 | Proeter & Gamble Company | Fat crystallization process |
| US3158490A (en) * | 1962-03-27 | 1964-11-24 | Procter & Gamble | Salad oils and method of making them |
| US3600186A (en) * | 1968-04-23 | 1971-08-17 | Procter & Gamble | Low calorie fat-containing food compositions |
| US3809711A (en) * | 1972-04-07 | 1974-05-07 | Procter & Gamble | Process for synthesizing specific complete mixed polyol esters |
| US3954976A (en) * | 1973-12-14 | 1976-05-04 | The Procter & Gamble Company | Pharmaceutical compositions for inhibiting absorption of cholesterol |
| US3963699A (en) * | 1974-01-10 | 1976-06-15 | The Procter & Gamble Company | Synthesis of higher polyol fatty acid polyesters |
| US4034083A (en) * | 1975-11-03 | 1977-07-05 | The Procter & Gamble Company | Compositions for inhibiting absorption of cholesterol |
| EP0236288B1 (en) * | 1986-02-20 | 1993-12-15 | The Procter & Gamble Company | Low calorie fat materials that eliminate laxative side effect |
-
1977
- 1977-02-02 IE IE213/77A patent/IE44458B1/en not_active IP Right Cessation
- 1977-02-08 DE DE19772705105 patent/DE2705105A1/en active Granted
- 1977-02-11 LU LU76751A patent/LU76751A1/xx unknown
- 1977-02-11 IT IT20238/77A patent/IT1075126B/en active
- 1977-02-11 NL NL7701460A patent/NL188503C/en not_active IP Right Cessation
- 1977-02-11 FR FR7703892A patent/FR2340737A1/en active Granted
- 1977-02-11 GB GB5716/77A patent/GB1579241A/en not_active Expired
- 1977-02-12 JP JP1453377A patent/JPS52120131A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2340737B1 (en) | 1981-01-09 |
| NL188503C (en) | 1995-05-16 |
| FR2340737A1 (en) | 1977-09-09 |
| GB1579241A (en) | 1980-11-19 |
| DE2705105A1 (en) | 1977-08-18 |
| NL7701460A (en) | 1977-08-16 |
| IT1075126B (en) | 1985-04-22 |
| JPS52120131A (en) | 1977-10-08 |
| DE2705105C2 (en) | 1987-06-11 |
| NL188503B (en) | 1992-02-17 |
| IE44458L (en) | 1977-08-12 |
| JPS6339568B2 (en) | 1988-08-05 |
| LU76751A1 (en) | 1977-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE34617E (en) | Vitaminized compositions for treating hypercholesterolemia | |
| US4034083A (en) | Compositions for inhibiting absorption of cholesterol | |
| US4005195A (en) | Compositions for treating hypercholesterolemia | |
| US4241054A (en) | Detoxifying lipophilic toxins | |
| US4849222A (en) | Mixtures for treating hypercholesterolemia | |
| US4264583A (en) | Gallstone dissolution compositions and method | |
| EP0309029B1 (en) | Cookies containing psyllium | |
| CA1340804C (en) | Mixed compositions for treating hypercholesterolemia | |
| Kritchevsky | Impact of red palm oil on human nutrition and health | |
| USRE33996E (en) | Compositions for treating hypercholesterolemia | |
| US5116610A (en) | Compositions for treating hypercholesterolemia | |
| USRE33885E (en) | Compositions for inhibiting absorption of cholesterol | |
| IE44458B1 (en) | Compositions for treating hypercholesterolemia | |
| US4962092A (en) | Compositions for treating duodenal ulcers | |
| US6821545B2 (en) | Low calorie fat materials that eliminate laxative side effect | |
| JP2716453B2 (en) | Composition for treating duodenal ulcer | |
| JPH0394656A (en) | Product with edible oil containing carotenoid | |
| WO1992010941A1 (en) | Edible fat-containing products containing vitamin e | |
| US5910317A (en) | Mixed compositions for treating hypercholesterolemia | |
| WO2002049457A1 (en) | The use of a non-absorbable, non-digestible lipid for the treatment of hyperbilirubinemia | |
| Akoh | Fat-based fat substitutes | |
| CASIMIR | Fat-Based Fat Substitutes | |
| IE60716B1 (en) | Low calorie fat materials that eliminate laxative side effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |